case study
AttoDiagnostics is part of the AttoGroup, based at Scottow Enterprise Park, having relocated after outgrowing their previous site in Norwich. The group offers various services, including DNA, drug and alcohol testing.
Spearheading innovation within the genetic and drug testing sector.
AttoDiagnostics is part of the AttoGroup. The company is based at Scottow Enterprise Park, having relocated after outgrowing their previous site in Norwich. Collectively the group offers a range of services including DNA, drug and alcohol testing, and work with a wide range of customers including regulators, academia, food & agriculture, local authorities, solicitors, mental health services, private individuals, and provide laboratory services for leading consumer brands and healthcare organisations.
AttoDiagnostics specialise in providing research and testing for brands, medical institutions and pharmacies to provide life-changing personalised healthcare solutions. They are one the of the UK’s leading genetic testing company.
The company has made significant investments in cutting edge technology to ensure that they are able to deliver a trusted service based on robust science. The services the business offers include:
Genotyping: Analysing genetic variations to provide insights into fitness, well-being, nutrigenetics, and methylation processes.
Pharmacogenetics: Assessing how genes affect an individual’s response to drugs, covering areas like antithrombotic agents, mental health, oncology, cardiovascular system agents, alimentary tract and metabolism, and respiratory system.
Next Generation Sequencing (NGS): Offering advanced sequencing services, including target sequencing, exome sequencing, and microbiome analyses (gut, vaginal, oral), as well as whole genome sequencing.
Bloodborne Infection Screening: Providing screening services for infections such as HIV, HCV, HBV, and syphilis
Molecular Diagnostics: Focusing on the detection of respiratory infections, sexual health issues, and gut health conditions.
Contract Research: Engaging in assay development, validation, and system evaluation to support scientific research and product development.
At AttoDiagnostics we are advancing personalised healthcare. Geonomics is the way forward. The NHS will be saving in excess of £2 billion a year. What we’re doing is one of the leading entities in the country. Being able to work in a facility with the space available and also the ample space to grow, makes it the most suitable environment for us to be able to operate in. Norfolk is very, very good. There is huge, huge room for growth. Prince Agyirey-Kwakye,
Chief Scientific Officer, Atto Group
